Posts

Posted on

Nasus Pharma Appoints Pharmaceutical Industry Veteran Brendan P. O’Grady as Chief Executive Officer to Lead Strategic Growth

TEL AVIV, Israel, July 28, 2026 (GLOBE NEWSWIRE) — Nasus Pharma Ltd. (NYSE: NSRX) (“Nasus”, “Nasus Pharma” or the “Company”), a clinical-stage pharmaceutical company focused on the development of innovative intranasal products, today announced the appointment of pharma industry veteran Brendan P. O’Grady as its Chief Executive Officer. Mr. O’Grady will lead the Company’s next phase of growth, with an initial focus on unlocking the commercial potential of NS002, advancing the Company’s pipeline and business development initiatives, and maximizing the value of its proprietary Nasax® intranasal technology platform. Mr. O’Grady succeeds Dan Teleman, with the leadership transition effective July 27, 2026.

“Brendan’s appointment reflects the Board’s commitment to advance Nasus to its next phase of growth, and represents a significant milestone in the Company’s evolution,” said Udi Gilboa, Chairman of the Board of Directors of Nasus Pharma. “As we advance NS002 toward a pivotal trial in the fourth quarter of 2026 and topline data readout the first quarter of 2027, our strategic focus is increasingly centered on pre-commercial planning. Brendan brings strategic vision, extensive experience in payors and reimbursement, and proven commercial leadership required to develop and execute this strategy. We are delighted to welcome Brendan to the Nasus team.”

“On behalf of the Board of Directors, I also extend our thanks to Dan Teleman for his service and many contributions to Nasus, and wish him continued success in his future endeavors,” concluded Mr. Gilboa.

“I am thrilled to be joining Nasus at such an important stage in the Company’s development,” said Mr. O’Grady. “NS002 presents an opportunity to address a significant unmet medical need in the treatment of anaphylaxis and represents a growing $2 billion market opportunity. In a market currently dominated by injectables, NS002’s rapid onset and intranasal administration offer patients and caregivers a potentially superior alternative for treating severe allergic reactions. Based on my 35 years of experience leading commercial strategy and go-to-market programs, I believe the Nasus portfolio represents a significant value generation opportunity, and I look forward to working with the entire Nasus leadership team to deliver the therapeutic promise of these assets to patients in need.”

Mr. O’Grady is a highly accomplished pharmaceutical executive with more than three decades of global leadership experience spanning corporate strategy, business development, commercialization, market access, strategic partnerships and global product launches. Mr. O’Grady has led multi-billion-dollar pharmaceutical businesses, developed and executed global commercialization strategies, established strategic pharmaceutical partnerships, and consistently created shareholder value across publicly traded healthcare companies. He spent 21 years at Teva Pharmaceuticals in a variety of commercial roles, rising to CEO of Teva USA and EVP North America Commercial while scaling profitability, growth, and productivity. He has also served as Chief Executive Officer of Assertio Holdings (Nasdaq: ASRT). Mr. O’Grady has served on a variety of public and private corporate boards and advisory committees. Most notably, he served as a director of the telehealth company, American Well Corporation (Amwell), from 2015 – 2021. While on the board of Amwell, he served as the compensation committee chair and as a member of the IPO committee. He also served with distinction as a member of the United States Department of Commerce, U.S. Investment Advisory Council from August 2019 through June of 2021. Mr. O’Grady holds a Bachelor of Science degree in Management Science from SUNY Geneseo (Geneseo State University, Geneseo, NY) and a Master of Business Administration from Baker University’s (Baldwin City, Kansas) School of Professional and Graduate Studies.

Additional information regarding Mr. O’Grady’s appointment will be furnished by the Company in a Report on Form 6-K with the U.S. Securities and Exchange Commission.

About Nasus Pharma

Nasus Pharma Ltd. (NYSE: NSRX) is a biopharmaceutical company advancing innovative intranasal therapies through its proprietary intranasal powder technology platform. The Company’s lead product candidate, NS002, is being developed as an intranasal epinephrine treatment for Type I allergic reactions, including anaphylaxis. In addition to NS002, Nasus is leveraging its proprietary technology platform to develop a growing pipeline of differentiated intranasal product candidates designed to provide rapid, reliable and patient-friendly drug delivery across multiple therapeutic areas.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other U.S. federal securities laws. Words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “target,” “aim,” “should,” “will”, “would,” or the negative of these words, similar expressions or variations of such words are intended to identify forward looking statements. For example, Nasus Pharma is using forward looking statements in this press release when it discusses: statements regarding the Company’s strategy to commercialize NS002 and unlocking its commercial potential; advancing the Company’s pipeline and future business development initiatives, maximizing the value of its proprietary Nasax intranasal technology platform; the next phase of Nasus Pharma’s growth; the Company advancing NS002 toward a pivotal trial in the fourth quarter of 2026 and topline data readout the first quarter of 2027; the increasing strategic focus on pre-commercial planning; the opportunity NS002 presents to address a significant unmet medical need; the believe that the Nasus portfolio represents a significant value generation opportunity; and the potential applications and promise of the Company’s proprietary intranasal technology platform. These forward-looking statements are based on current expectations and assumptions and involve risks and uncertainties that could cause actual results to differ materially from those expressed or implied. Readers are cautioned not to place undue reliance on these forward-looking statements. The Company undertakes no obligation to update or revise these forward-looking statements except as required by applicable law.

Company Contact

Nasus Pharma Ltd.


[email protected]

Investor Contact

Mike Moyer

LifeSci Advisors

+1-617-308-4306


[email protected]



Posted on

3D Systems Enables First FDA Clearance for Implant from a Point-of-Care Institution

  • Collaboration with Defense Health Agency (DHA) enables Walter Reed 3D Medical Application Center (3D MAC) to achieve first FDA-cleared medical device
  • First-ever FDA clearance for an implant granted to a point-of-care institution
  • Reinforces 3D Systems’ leadership in guiding healthcare partners from concept to regulatory clearance and commercialization of 3D-printed, patient-specific devices

ROCK HILL, S.C., July 28, 2026 (GLOBE NEWSWIRE) — Today, 3D Systems (NYSE: DDD) announced its role in enabling the Defense Health Agency (DHA) and the Walter Reed National Military Medical Center’s 3D Medical Applications Center (3D MAC) to achieve U.S. Food and Drug Administration (FDA) premarket clearance for the 3D MAC Titanium Cranial Plate (TCP) System, the first-ever FDA-cleared implant granted to a point-of-care institution. 3D MAC’s patient-specific Titanium Cranial Plate (TCP) will be used to treat U.S. active duty personnel and war fighters suffering from traumatic head injuries around the world.

Advancing Point-of-Care Manufacturing Through Collaboration

This milestone represents the culmination of a multi-year collaboration between 3D Systems and 3D MAC to advance additive manufacturing in clinical environments. The 3D Medical Applications Center, based at Walter Reed National Military Medical Center, specializes in patient-specific anatomical models, surgical guides, and implants to support personalized care for service members and veterans.

“We believe point-of-care manufacturing is transforming the future of healthcare by bringing personalized medical devices closer to the patient. Our unique collaborations with the U.S. Defense Health Agency and the Department of Veterans Affairs underscore our leadership in this space and reinforce our commitment to expanding this business as a long-term growth driver for 3D Systems.” said Jeff Graves, President and CEO of 3D Systems.

Throughout the engagement, 3D Systems worked closely with 3D MAC to establish a robust quality management system (QMS) and provided support across the full development lifecycle, from design and validation through regulatory submission. The FDA clearance of the Titanium Cranial Plate System marks 3D MAC’s first-ever FDA-cleared medical device.

Enabling Regulatory Readiness and Clinical Innovation

3D Systems provided expertise in process controls, device design optimization, additive manufacturing workflows, and regulatory strategy to support 3D MAC in achieving premarket clearance. This collaboration enabled the transition from concept to an FDA-cleared implant manufactured at the point-of-care.

Natalie Byrnes, Manager of Product Development – Patient Specific Medical Technology, 3D Systems said “This clearance underscores the power of combining clinical innovation with deep expertise in additive manufacturing and regulatory compliance. We are honored to help enable expanded access to personalized care delivered at the point of treatment.”

Industry Leadership and Future Opportunities

The clearance establishes multiple industry firsts, including the first FDA-cleared implant granted to a point-of-care institution and 3D MAC’s first FDA-cleared medical device. It reinforces 3D Systems’ leadership in enabling point-of-care manufacturing and highlights its ability to help healthcare institutions navigate the path from concept through regulatory clearance and commercialization.

This achievement further strengthens 3D Systems’ relationships with the Defense Health Agency and the Department of Veterans Affairs and positions the company to support future initiatives in advanced, patient-specific medical manufacturing.

The clearance is listed on the FDA website under submission number K253116.

About 3D Systems

For 40 years Chuck Hull’s curiosity and desire to improve the way products were designed and manufactured gave birth to 3D printing, 3D Systems, and the additive manufacturing industry. Since then, that same spark continues to ignite the 3D Systems team as we work side-by-side with our customers to change the way industries innovate. As a full-service solutions partner, we deliver industry-leading 3D printing technologies, materials and software to high-value markets such as medical and dental; aerospace, space and defense; transportation and motorsports; AI infrastructure; and durable goods. Each application-specific solution is powered by the expertise and passion of our employees who endeavor to achieve our shared goal of Transforming Manufacturing for a Better Future. More information on the company is available at www.3dsystems.com.

Forward-Looking
Statements

Certain statements made in this release that are not statements of historical or current facts are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 including statements regarding the timing of product launches, regulatory approvals, market opportunities, expected revenue impact, and shareholder value. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the company to be materially different from historical results or from any future results or projections expressed or implied by such forward-looking statements. In many cases, forward-looking statements can be identified by terms such as “believes,” “belief,” “expects,” “may,” “will,” “estimates,” “intends,” “anticipates” or “plans” or the negative of these terms or other comparable terminology. Forward-looking statements are based upon management’s beliefs, assumptions, and current expectations and may include comments as to the company’s beliefs and expectations as to future events and trends affecting its business and are necessarily subject to uncertainties, many of which are outside the control of the company. The factors described under the headings “Forward-Looking Statements” and “Risk Factors” in the company’s periodic filings with the Securities and Exchange Commission, as well as other factors, could cause actual results to differ materially from those reflected or predicted in forward-looking statements. Although management believes that the expectations reflected in the forward-looking statements are reasonable, forward-looking statements are not, and should not, be relied upon as a guarantee of future performance or results, nor will they necessarily prove to be accurate indications of the times at which such performance or results will be achieved. The forward-looking statements included are made only as of the date of the statement. 3D Systems undertakes no obligation to update or review any forward-looking statements made by management or on its behalf, whether as a result of future developments, subsequent events or circumstances or otherwise.

Investor Contact: [email protected]

Media Contact: [email protected]



Posted on

PMGC Holdings Inc. Announces Strategic Investment in Precision Aerospace & Defense Group and Long-Term Aerospace and Defense Manufacturing Agreement Through A&B Aerospace Inc.

Two-year renewable long-term agreement establishes A&B Aerospace as a precision manufacturing supplier to PAD Group and its subsidiaries across aerospace and defense programs. Agreement enables A&B Aerospace to support purchase orders connected to U.S. federal government prime contracts, subject to applicable FAR and DFARS requirements.

NEWPORT BEACH, Calif., July 28, 2026 (GLOBE NEWSWIRE) — PMGC Holdings Inc. (NASDAQ: ELAB) (the “Company,” “PMGC,” “we,” or “our”), a diversified holding company executing a precision manufacturing growth strategy across the aerospace and defense supply chain, today announced that its wholly owned subsidiary, A&B Aerospace, Inc. (“A&B Aerospace”), has entered into a Long-Term Agreement (the “Agreement”) with Precision Aerospace & Defense Group, Inc. (“PAD Group”) to manufacture and supply precision-machined aerospace and defense components.

The Agreement, effective July 23, 2026, establishes a two-year framework under which PAD Group and its subsidiaries may issue purchase orders to A&B Aerospace for precision-manufactured components supporting aerospace and defense programs. The Agreement automatically renews for successive one-year periods unless either party provides notice of non-renewal, creating the foundation for a durable, multi-year manufacturing relationship. Each purchase order will specify the applicable products, quantities, pricing, delivery schedules, and other requirements. The Agreement does not include a guaranteed minimum purchase volume or revenue commitment.

Importantly, the Agreement positions A&B Aerospace to support purchase orders associated with U.S. federal government prime contracts, subject to the applicable Federal Acquisition Regulation (FAR) and Defense Federal Acquisition Regulation Supplement (DFARS) requirements incorporated into the relevant purchase orders. PMGC believes this framework expands A&B Aerospace’s addressable opportunity within the U.S. defense industrial base, where demand for qualified, U.S.-based precision manufacturing capacity continues to grow across aircraft, defense systems, and mission-critical component programs.

The Agreement reflects continued commercial momentum across PMGC’s precision manufacturing platform, which currently includes A&B Aerospace, AGA Precision Systems, and SVM Machining. PMGC believes the relationship further validates the high-tolerance CNC machining, complex assembly, and engineered component capabilities of its operating companies, and demonstrates the platform’s ability to win long-term programs with aerospace and defense customers that require rigorous quality systems, reliability, and on-time delivery. The Company expects to pursue additional long-term agreements and program awards across its manufacturing subsidiaries as it continues to scale its aerospace and defense footprint.

Strategic Equity Investment and Manufacturing Capacity Partnership

PMGC Capital LLC, a wholly owned subsidiary of PMGC, also invested $500,000 as a strategic investment in PAD Group’s offering of Series F Convertible Preferred Stock, pursuant to the terms of PAD Group’s private offering memorandum for the Series F financing.

PMGC believes the contemplated transactions in the Term Sheet align the long-term interests of both organizations. PAD Group would gain access to qualified, U.S.-based precision manufacturing capacity across PMGC’s platform as it scales its aerospace and defense programs, while PMGC would participate directly in PAD Group’s growth through an equity investment and could benefit from potential incremental manufacturing volume across its operating companies. The proposed investment is separate from the Agreement, under which pricing, volumes, and delivery requirements are established on a purchase order by purchase order basis.

The Term Sheet is non-binding, and the proposed investment and service agreement remain subject to completion of due diligence, negotiation and execution of definitive agreements, required corporate approvals, and other customary closing conditions. There can be no assurance that the proposed investment or service agreement will be completed on the terms contemplated, or at all.

About PMGC Holdings Inc.

PMGC Holdings Inc. is a diversified holding company that manages and grows its portfolio through strategic acquisitions, investments, and development across various industries. We are committed to exploring opportunities in multiple sectors to maximize growth and value. For more information, please visit https://www.pmgcholdings.com.

About A&B Aerospace, Inc.

Founded in 1948, A&B Aerospace is a precision aerospace manufacturing company specializing in high-tolerance machining, complex assemblies, and engineered components for the aerospace and defense industries. Headquartered in Azusa, California, the company provides advanced CNC machining, grinding, honing, and precision deburring services for mission-critical applications. With decades of manufacturing expertise, A&B Aerospace supports leading aerospace customers through a commitment to quality, reliability, and on-time delivery. The company operates a modern manufacturing platform with advanced multi-axis machining capabilities and maintains AS9100 and ISO 9001 certifications to meet the rigorous standards of the global aerospace industry.

For more information, visit https://www.abaerospace.com.

About Precision Aerospace & Defense Group, Inc.

Precision Aerospace & Defense Group, Inc. is headquartered in Overland Park, Kansas, and operates within the aerospace and defense sector, working with industry participants and supply-chain partners to support customer and program requirements across aerospace and defense markets.

Forward-Looking Statements

Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Words such as “believes,” “expects,” “plans,” “potential,” “would” and “future” or similar expressions such as “look forward” are intended to identify forward-looking statements. Forward-looking statements are made as of the date of this press release and are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy, activities of regulators and future regulations and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results. Therefore, you should not rely on any of these forward-looking statements. These and other risks are described more fully in PMGC’s filings with the United States Securities and Exchange Commission (“SEC”), including the “Risk Factors” section of the Company’s Annual Report on Form 10-K for the year ended December 31, 2025, filed with the SEC on March 30, 2026, and its other documents subsequently filed with or furnished to the SEC. Investors and security holders are urged to read these documents free of charge on the SEC’s web site at www.sec.gov. All forward-looking statements contained in this press release speak only as of the date on which they were made. Except to the extent required by law, the Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

Investor Relations Contact

[email protected]



Posted on

Palvella Therapeutics to Host Second Quarter 2026 Financial Results and Corporate Update Conference Call on August 4, 2026

WAYNE, Pa., July 28, 2026 (GLOBE NEWSWIRE) — Palvella Therapeutics, Inc. (Palvella or the “Company”) (Nasdaq: PVLA), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for serious, rare skin diseases and vascular malformations for which there are no U.S. Food and Drug Administration (FDA)-approved therapies, announced today that it will report its second quarter 2026 financial results before market open on Tuesday, August 4, 2026. Palvella management will host a conference call for investors at 8:30 a.m. ET on that same day to discuss the results and provide a corporate update.

To access the live webcast, including presentation slides, please click here or visit the “Events & Presentations” section of Palvella’s website. To access the conference call by phone, register using this link, and you will be provided with dial-in details. A replay of the webcast will be available approximately two hours after the conclusion of the call and will remain archived for 90 days under the “Events & Presentations” section of the Company’s website at www.palvellatx.com.

About Palvella Therapeutics

Founded and led by rare disease biotech veterans, Palvella Therapeutics, Inc. (Nasdaq: PVLA) is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients living with serious, rare skin diseases and vascular malformations for which there are no FDA-approved therapies. Palvella is developing a broad pipeline of product candidates based on its patented QTORIN™ platform, with an initial focus on serious, rare skin diseases and vascular malformations, many of which are lifelong in nature. Palvella’s lead product candidate, QTORIN™ 3.9% rapamycin anhydrous gel (QTORIN™ rapamycin), is currently being developed for the treatment of microcystic lymphatic malformations, cutaneous venous malformations, and clinically significant angiokeratomas. Palvella’s second product candidate, QTORIN™ pitavastatin, is currently being developed for the treatment of disseminated superficial actinic porokeratosis. For more information, please visit www.palvellatx.com or follow Palvella on LinkedIn or X (formerly known as Twitter).

QTORIN™ rapamycin and QTORIN™ pitavastatin are for investigational use only and neither has been approved by the FDA or by any other regulatory agency for any indication.

Contact Information

Investors

Wesley H. Kaupinen
Founder and Chief Executive Officer
Palvella Therapeutics
[email protected]

Media

Marcy Nanus
Vice President of Investor Relations and Corporate Affairs
Palvella Therapeutics
[email protected]



Posted on

ZenaTech’s ZenaDrone Begins Testing Phase for Interceptor P-1 Counter-UAS Drone Platform

Low-cost VTOL autonomous interceptor advances company’s integrated Counter-UAS portfolio and defense system

VANCOUVER, British Columbia, July 28, 2026 (GLOBE NEWSWIRE) — ZenaTech, Inc. (Nasdaq: ZENA) (FSE: 49Q) (BMV: ZENA) (“ZenaTech”), a technology solution provider specializing in AI (Artificial Intelligence) drone, Drone as a Service (DaaS), enterprise SaaS, and Quantum Computing solutions, today announces that its ZenaDrone subsidiary has commenced the initial flight testing phase of its Interceptor P-1, the Company’s low-cost, one-way autonomous counter-drone platform designed to physically intercept hostile unmanned aerial systems (UAS).

The commencement of testing represents a significant step in expanding the Company’s Counter-UAS drone portfolio and integrated defense system. The Interceptor P-1 is designed as a vertical takeoff and landing (VTOL), one-way autonomous interceptor intended to provide an affordable alternative to traditional missile-based drone defense systems and asymmetric warfare combatting drone swarms with multi-million-dollar missiles.

“Our engineering team has reached an important milestone as we begin flight testing of the Interceptor P-1,” said Shaun Passley, Ph.D., CEO of ZenaTech. “This program is focused on validating the aircraft’s flight characteristics, autonomous capabilities, and system reliability before advancing to increasingly complex interception exercises. We believe the demand for affordable counter-drone solutions continues to grow globally as military organizations and critical infrastructure operators seek cost-effective methods to defend against rapidly evolving drone threats.”

The initial flight test campaign, to be conducted by the ZenaDrone engineering team at the company’s testing range near its Mesa, Arizona facility, will evaluate vertical takeoff and landing performance, high-speed maneuverability, target acquisition and tracking algorithms, guidance controls, and communications reliability. Subsequent phases are expected to include autonomous target pursuit, moving-target intercept exercises, multi-drone operational scenarios, and integration with the Company’s Zena AI Counter-UAS command software.

The Interceptor P-1 prototype was first disclosed in March 2026 which included a target selling price of under $5,000 USD, positioning it as a significantly lower-cost alternative to traditional missile-based and laser-based intercept systems for modern asymmetric drone warfare. In April 2026, ZenaTech provided a further update on its expanding defense manufacturing footprint, announcing the registration of Phoenix Aero LLC, a Ukrainian entity based in Lviv, which is being established to support future manufacturing and testing of the Interceptor P-1 and other counter-UAS systems as part of the Company’s EMEA operations. ZenaTech is in the process of setting up this office.

The Company believes that low-cost autonomous interceptors will play an increasingly important role in defending military bases, in maritime situations, at airports, energy facilities, government infrastructure, ports, border operations, and other critical assets against hostile drones and drone swarm attacks.

The Interceptor P-1 is being engineered to operate as part of ZenaTech’s broader Counter-UAS ecosystem, integrating with the Company’s AI-powered threat detection, classification, and autonomous swarm command software. The complete architecture is intended to enable a single operator to monitor, identify, prioritize, and respond to multiple airborne threats simultaneously using coordinated autonomous interceptor drones.

ZenaTech expects to continue expanding the testing program throughout 2026 as development progresses toward future operational demonstrations and customer evaluations. Further updates will be provided as additional milestones are reached.

About ZenaTech


ZenaTech
 (Nasdaq: ZENA) (FSE: 49Q) (BMV: ZENA) is a technology company specializing in AI drone, Drone as a Service (DaaS), enterprise SaaS and Quantum Computing solutions for mission-critical applications for business, government and defense. Since 2017, the Company has leveraged its software development expertise and grown its drone design and manufacturing capabilities through ZenaDrone, to innovate and improve customer inspection, monitoring, safety, security, compliance, and surveying processes. With enterprise software customers using branded solutions in law enforcement, government, and industrial sectors, and drones being implemented in these plus agriculture, defense, and logistics sectors, ZenaTech’s portfolio of solutions helps drive speed, accuracy, and cost savings. The Company operates through global offices in North America, Europe, Taiwan, and UAE, and is growing its DaaS business and global network of locations through acquisitions.

About ZenaDrone


ZenaDrone
, a wholly owned subsidiary of ZenaTech, develops and manufactures autonomous drone solutions that can incorporate machine learning software, AI, predictive modeling, Quantum Computing, and other software and hardware innovations. Created to revolutionize the hemp farming sector, its specialization has grown to multifunctional drone solutions for surveying, monitoring, inspection, tracking, process automation, and defense applications.

Currently, the ZenaDrone 1000 drone is used for crop management applications and critical field cargo applications in the defense sector, the IQ Nano indoor drone is used for inventory management and security in the warehouse and logistics sectors, the IQ Square is an outdoor drone designed for power washing and inspections use in commercial and government sectors, and the IQ Quad is for land surveys. ZenaDrone operates three global manufacturing facilities in Arizona, Dubai, and Taiwan, and is advancing counter-UAS maritime interceptor drones and an integrated defense system.

Contacts for more information:

Company, Investors, and Media:
Linda Montgomery
ZenaTech
312-241-1415

Investors:
Michael Mason
CORE IR
[email protected]

Safe Harbor

This press release and related comments by management of ZenaTech, Inc. include “forward-looking statements” within the meaning of U.S. federal securities laws and applicable Canadian securities laws. These forward-looking statements are subject to the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. This forward-looking information relates to future events or future performance of ZenaTech and reflects management’s expectations and projections regarding ZenaTech’s growth, results of operations, performance, and business prospects and opportunities. Such forward-looking statements reflect management’s current beliefs and are based on information currently available to management. In some cases, forward-looking information can be identified by terminology such as “may”, “will”, “should”, “expect”, “plan”, “anticipate”, “aim”, “seek”, “is/are likely to”, “believe”, “estimate”, “predict”, “potential”, “continue” or the negative of these terms or other comparable terminology intended to identify forward-looking statements. Forward-looking information in this document includes, but is not limited to ZenaTech’s expectations regarding its revenue, expenses, production, operations, costs, cash flows, and future growth; expectations with respect to future production costs and capacity; ZenaTech’s ability to deliver products to the market as currently contemplated, including its drone products including ZenaDrone 1000, IQ Square and IQ Nano; ZenaTech’s ability to develop products for markets as currently contemplated; ZenaTech’s anticipated cash needs and its needs for additional financing; ZenaTech’s intention to grow the business and its operations and execution risk; expectations with respect to future operations and costs; the volatility of stock prices and market conditions in the industries in which ZenaTech operates; political, economic, environmental, tax, security, and other risks associated with operating in emerging markets; regulatory risks; unfavorable publicity or consumer perception; difficulty in forecasting industry trends; the ability to hire key personnel; the competitive conditions of the industry and the competitive and business strategies of ZenaTech; ZenaTech’s expected business objectives for the next twelve months; ZenaTech’s ability to obtain additional funds through the sale of equity or debt commitments; investment capital and market share; the ability to complete any contemplated acquisitions; changes in the target markets; market uncertainty; ability to access additional capital, including through the listing of its securities in various jurisdictions; management of growth (plans and timing for expansion); patent infringement; litigation; applicable laws, regulations, and any amendments affecting the business of ZenaTech and other related risks and uncertainties disclosed under the heading “Risk Factors” in the Company’s Form F-1, Form 20-F and other filings filed with the United States Securities and Exchange Commission (the “SEC”) on EDGAR through the SEC’s website at www.sec.gov. The Company undertakes no obligation to update forward-looking information except as required by applicable law. Such forward-looking information represents management’s best judgment based on information currently available. No forward-looking statement can be guaranteed and actual future results may vary materially. Accordingly, readers are advised not to place undue reliance on forward-looking statements or information.



Posted on

Bending Spoons enters into €500 million SACE-backed term loan facility

Bending Spoons enters into €500 million SACE-backed term loan facility

MILAN–(BUSINESS WIRE)–
Bending Spoons S.p.A. (NASDAQ: BSP) announced today that it has entered into a new €500 million medium-long-term financing provided by HSBC Continental Europe (acting as Sole Coordinator and MLA), Intesa Sanpaolo S.p.A. (acting as SACE Agent and MLA), and BPER Banca Corporate & Investment Banking (acting as Structuring Advisor and MLA). The facility, which matures in March 2031, benefits from a guarantee provided by SACE, in advancement of SACE’s mission to support the international growth of Italian businesses.

Together with €495 million of additional term loan A financing and a €490 million increase in commitments under Bending Spoons’ revolving credit facility, the transaction brings the aggregate amount of new and expanded facilities agreed by Bending Spoons from the beginning of the second quarter to €1.49 billion. Both the term loan A financing and the additional revolving credit facility commitments are available for general corporate purposes and acquisitions, with each of the facilities maturing in March 2031.

“We are grateful for the continued support of SACE and our financing partners,” said Davide Scarpazza, co-chief financial officer of Bending Spoons. “These arrangements enhance our capital resources and provide additional financial flexibility. Our aim is to maximize long-term value per share, and we remain focused on deploying capital in a disciplined way to generate attractive risk-adjusted returns, primarily through acquisitions.”

“Bending Spoons is a strong example of how Italian innovation, combined with exceptional talent density, can compete and grow on a global scale,” said Michele Pignotti, Chief Executive Officer of SACE. “This transaction confirms SACE’s commitment to standing alongside leading Italian companies that invest in innovation, expand into global markets, and contribute to the competitiveness of Italy’s innovation ecosystem.”

About Bending Spoons

Bending Spoons is built on the conviction that operational excellence enables efficient growth through acquisitions. It acquires digital businesses, implements deep transformations and ongoing optimizations to sustainably expand earnings, and reinvests in additional acquisitions, thereby continuing the compounding cycle. The company has executed this strategy for more than a decade and, to date, has never sold a material business.

Bending Spoons strives to envision the most successful version of an acquired business, and works to close the gap between its current state and that vision as quickly and completely as possible. The transformation is typically deep and entails reorganizing teams, overhauling technology, redesigning user interfaces, accelerating product development, and enhancing marketing and monetization. AI is often both a central component of the vision and a key tool in implementing the transformation.

Bending Spoons’ performance is driven by its Platform—comprising its people, proprietary technologies, and proprietary data—and reflects an intense focus on achieving exceptional talent density, cultural strength, and technical capabilities.

Bending Spoons’ main businesses include AOL, Brightcove, Eventbrite, Evernote, Harvest, komoot, Remini, StreamYard, Vimeo, and WeTransfer. In March 2026, the company served over 500 million monthly active users and more than 9 million monthly paying customers.

About SACE

SACE is Italy’s Export Credit Agency, wholly owned by the Ministry of Economy and Finance. It specializes in supporting the growth of Italian companies through a wide range of instruments and solutions to foster exports and competitiveness, including risk management and protection, financial guarantees, factoring, advisory services, and business matching. With a network of export advisors across 23 offices in Italy and in high-potential markets for Made in Italy, SACE manages a portfolio of insured operations and guaranteed investments worth around €290 billion across 200 markets worldwide.

Forward Looking Statements

This press release contains “forward-looking statements” within the meaning of the safe-harbor provisions of the Private Securities Litigation Reform Act of 1995, including statements regarding the intended use of the financing facilities, Bending Spoons’ capital-allocation strategy, and potential future acquisitions. Words such as “expect,” “anticipate,” “believe,” “intend,” “may,” “will,” “could,” “should,” “plan,” “target,” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.

Forward-looking statements are subject to risks, uncertainties, and assumptions, many of which are beyond Bending Spoons’ control, that could cause actual results to differ materially from those expressed or implied by such statements. These risks include Bending Spoons’ ability to deploy capital on attractive terms, identify and complete acquisitions, successfully integrate and transform acquired businesses, service its indebtedness, and raise additional capital when required, as well as the other risks described in Bending Spoons’ filings with the U.S. Securities and Exchange Commission. The forward-looking statements in this press release speak only as of its date. Except as required by law, Bending Spoons undertakes no obligation to update or revise them.

For more information, visit the Bending Spoons website and investor relations website.

Bending Spoons logos and photographs: media assets

Investors: [email protected]

Media: [email protected]

KEYWORDS: Europe United States Italy North America

INDUSTRY KEYWORDS: Professional Services Data Management Technology Other Technology Finance Artificial Intelligence Banking

MEDIA:

Logo
Logo
Posted on

PHINIA to Participate in Deutsche Bank Chicago Industrials Summit

PHINIA to Participate in Deutsche Bank Chicago Industrials Summit

AUBURN HILLS, Mich.–(BUSINESS WIRE)–
PHINIA Inc. (NYSE: PHIN), a diversified, industrial supplier and global leader in the development of fuel systems, electrical systems and aftermarket solutions, announced today that it will participate in the Deutsche Bank Chicago Industrials Summit on Wednesday, August 12, 2026. Conference participation will be in-person and include a Q&A session to discuss dynamics across the various markets PHINIA serves around the world and the Company’s business.

PHINIA’s President and CEO, Brady Ericson, and Senior VP and ​CFO, Chris Gropp, will participate in the Q&A session moderated by Brian Willer, Managing Director, InvestmentBank at Deutsche Bank.The event will be webcast and available on PHINIA’s Investor Relations website. Event information can be found below.

Event Title: Deutsche Bank Chicago Industrials Summit

Event Date: Wednesday, August 12, 2026, 9:00 AM Eastern Time (8:00 AM Central Daylight Time)

Live Webcast Info: https://cc.webcasts.com/deut001/081126a_js/?entity=3_7CPQFWY

About PHINIA

PHINIA is a diversified, industrial supplier and global leader in the development of fuel systems, electrical systems, and aftermarket solutions, with a strong portfolio of trusted brands that includes DELPHI®, DELCO REMY® and HARTRIDGETM. With over 100 years of manufacturing expertise and industry relationships, PHINIA has approximately 12,500 talented employees and over 40 locations in 20 countries and is headquartered in Auburn Hills, Michigan, USA.

Our systems and solutions are designed to keep combustion engines operating at peak performance across a variety of applications: medium- and heavy-duty commercial vehicle (on-road vehicles used for commercial transport classified class 4-8, 14,001 pounds or heavier), light commercial vehicle (on-road vehicles used for commercial transport classified as class 1-3, 14,000 pounds or lighter), light passenger vehicle (on-road vehicles used primarily for carrying passengers), and off-highway, industrial, and other (including construction and agricultural machinery, vocational vehicles, marine, industrial applications, power generation, and aerospace and defense).

PHINIA’s service solutions include vehicle repair and replacement parts, offering both new and remanufactured products through the original equipment manufacturer dealer network and the independent aftermarket channel.

By delivering high-performance solutions today and investing in advanced technologies to unlock the potential of alternative fuels in contributing to lower carbon mobility, PHINIA is shaping a more efficient and sustainable future.

© 2026 PHINIA Inc. All Rights Reserved.

(DELCO REMY is a registered trademark of General Motors LLC, licensed to PHINIA Technologies Inc.)

Cautionary Statement Regarding Forward-Looking Statements

This event may contain forward-looking statements within the meaning of U.S. federal securities laws. Forward-looking statements are statements other than historical fact that provide current expectations or forecasts of future events based on certain assumptions and are not guarantees of future performance. Forward-looking statements use words such as “anticipate,” “believe,” “continue,” “could,” “designed,” “effect,” “estimate,” “evaluate,” “expect,” “forecast,” “goal,” “initiative,” “intend,” “likely,” “may,” “outlook,” “plan,” “potential,” “predict,” “project,” “pursue,” “seek,” “should,” “target,” “when,” “will,” “would,” and other words of similar meaning.

Forward-looking statements are subject to risks, uncertainties, and factors relating to our business and operations, all of which are difficult to predict and which could cause our actual results to differ materially from the expectations expressed in or implied by such forward-looking statements. Risks, uncertainties, and factors that could cause actual results to differ materially from those implied by these forward-looking statements include, but are not limited to: adverse changes in general business and economic conditions, including recessions, adverse market conditions or downturns and other factors, including geopolitical tensions and related trade restrictions, impacting the global transportation and industrial equipment industries; our inability to deliver new products, services and technologies in response to changing consumer preferences and evolving exhaust emissions regulations, or acceleration of the market for electric vehicles or deceleration of the market for alternative fuel technologies, including for use in internal combustion engines; competitive industry conditions; failure to identify, consummate, effectively integrate or realize the expected benefits from acquisitions, partnerships or other strategic investments; failure of or disruption in our technology infrastructure, including a disruption related to cybersecurity; pricing pressures from customers; elevated inflation rates and volatility in the costs of commodities used in the production of our products; difficulties launching new machine, engine or vehicle programs; changes in U.S. and foreign administrative policy, including increases in tariffs, changes to existing trade agreements and import or export licensing requirements and exchange controls, and any resulting changes in international trade relations; our inability to identify, attract, retain and develop a qualified global workforce; our inability to protect our intellectual property; failure to achieve the anticipated savings and benefits from restructuring and other actions, including those intended to improve future profitability and competitiveness, optimize our product portfolio and operations and execute our strategy; extraordinary events, including natural disasters or extreme weather events, political disruptions, terrorist attacks, pandemics or other public health crises, and acts of war; risks related to our international operations; economic, geopolitical, social and market conditions impacting our business in China; supply chain disruptions, including due to U.S. and foreign government action; our reliance on a limited number of OEM customers; work stoppages, production shutdowns and similar events or conditions; liabilities related to product warranties, litigation and other claims; current and future environmental, health and safety, human rights and other laws and regulations related to corporate sustainability; tax audits or similar processes, and changes in tax laws or tax rates taken by taxing authorities; governmental investigations and related proceedings; the impacts of climate change, regulations related to climate change, various stakeholders’ emphasis on reducing the impacts of climate change and other related matters; compliance with and changes in other laws and regulations impacting our operations; impairment charges on goodwill, indefinite-lived intangible assets and long-lived assets; changes in interest rates and asset returns that increase our pension funding obligations; restrictive covenants and other requirements impacting our financial and operating flexibility pursuant to the agreements governing our indebtedness; risks relating to the Spin-Off, including a determination that the Spin-Off does not qualify as tax-free for U.S. federal income tax purposes, our or our Former Parent’s failure to perform under, or additional disputes that may arise between the parties relating to, various transaction agreements executed in connection with the Spin-Off and any amendments and restatements thereto, and the availability of, and our ability to use, various credits and offsets detailed in such agreements or the settlement agreement between the Company and our Former Parent; and other risks and uncertainties described our reports filed from time to time with the Securities and Exchange Commission.

We caution attendees not to place undue reliance upon any such forward-looking statements, which speak only as of the date they are made. We undertake no obligation to publicly update forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

IR contact:

Gordon Muir

Vice President and Treasurer

[email protected]

+1 574-210-5713

Media contact:

Kevin Price

Global Brand & Communications Director

[email protected]

+44 (0) 7795 463871

Category: IR

KEYWORDS: Illinois Michigan United States North America

INDUSTRY KEYWORDS: Off-Road Trucks & SUVs Automotive Manufacturing Other Transport Trucking Fleet Management Manufacturing Rail Maritime Aftermarket Transport Automotive Other Energy Oil/Gas Alternative Vehicles/Fuels Coal Alternative Energy Energy General Automotive

MEDIA:

Logo
Logo
Posted on

The Beachbody Company, Inc. Announces Second Quarter 2026 Earnings Release Date, Conference Call, and Webcast

The Beachbody Company, Inc. Announces Second Quarter 2026 Earnings Release Date, Conference Call, and Webcast

EL SEGUNDO, Calif.–(BUSINESS WIRE)–
The Beachbody Company, Inc. (NASDAQ: BODI) (“BODi” or the “Company”), the proactive wellness company delivering nutrition, supplements, and proven fitness programs that help people take control of their health inside and out, will release its second quarter 2026 results on Monday, August 10, 2026, after the U.S. stock market closes. The Company will host a conference call at 5:00 p.m. (Eastern Time) that day to discuss the results.

The toll-free dial-in for the conference call is (833) 461-5787 (U.S. & Canada), or click here for Global Dial-In Numbers. The conference ID is 309733825. A live webcast of the conference call will also be available on the Company’s investor relations website at https://investors.thebeachbodycompany.com/. After the conference call, a webcast replay will remain available on the investor relations section of the Company’s website for one year.

About BODi and The Beachbody Company, Inc.

BODi is the proactive wellness company delivering nutrition, supplements and proven fitness programs that help people take control of their health inside and out. With nearly three decades of experience, BODi, formerly Beachbody, has evolved from a leader in home fitness into a comprehensive health and fitness ecosystem designed to help people achieve their goals and lead healthier, more fulfilling lives. Anchored by science-backed nutrition solutions like Shakeology and supported by its portfolio of proven fitness and habit-building programs, including P90X and INSANITY, BODi is creating a more accessible and effective path to long-term health.

Since its inception, BODi has supported more than 30 million customers in achieving lasting results. The company continues to innovate across nutrition and digital fitness to deliver simple, proven solutions for modern lifestyles.

To subscribe and shop, visit BODi.com. For company and investor information, please visit TheBeachbodyCompany.com.

Investor Relations

[email protected]

KEYWORDS: California United States North America

INDUSTRY KEYWORDS: Teens Vitamins/Supplements Women Fitness & Nutrition Men Family Food/Beverage Consumer Health Retail

MEDIA:

Posted on

S&P Global Reports Second Quarter Results

PR Newswire

NEW YORK, July 28, 2026 /PRNewswire/ — S&P Global (NYSE: SPGI) today reported second quarter results. The Company’s earnings release and supplemental materials are available at http://investor.spglobal.com/Quarterly-Earnings. 

S&P Global Logo

Supplemental Information/Conference Call/Webcast Details:  The Company’s senior management will review the second quarter 2026 earnings results on a conference call scheduled for today, July 28, at 8:30 a.m. EDT. Additional information presented on the conference call, and the Company’s supplemental slide content may be found on the Company’s Investor Relations Website at http://investor.spglobal.com/Quarterly-Earnings. 

The Webcast will be available live and in replay at http://investor.spglobal.com/Quarterly-Earnings. 

About S&P Global 
S&P Global (NYSE: SPGI) enables businesses, governments, and individuals with trusted data, expertise and technology to make decisions with conviction. We are Advancing Essential Intelligence through world-leading benchmarks, data, and insights that customers need in order to plan confidently, act decisively, and thrive in a rapidly changing global landscape.

From helping our customers assess new investments across the capital and commodities markets to navigating the energy expansion, acceleration of artificial intelligence, and evolution of public and private markets, we enable the world’s leading organizations to unlock opportunities, solve challenges, and plan for tomorrow – today. Learn more at www.spglobal.com.

Investor Relations:  http://investor.spglobal.com 

Contact:

Investor Relations: 
Mark Grant
Senior Vice President, Investor Relations and Treasurer
Tel:  +1 (347) 640-1521
[email protected] 

Media: 
Christina Twomey
Chief Communications Officer
Tel:  +1 (646) 407-3001
[email protected] 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/sp-global-reports-second-quarter-results-302836420.html

SOURCE S&P Global

Posted on

DCX’s DexTrader Announces Upgrade, Targeting On-Chain Yield-Bearing Collateralized Derivatives Data Services Segment

NEW YORK, July 28, 2026 (GLOBE NEWSWIRE) — Digital Currency X Technology Inc. (Nasdaq: DCX) (“DCX” or the “Company”), a digital asset treasury management company, today announced that DexTrader, the on-chain data platform of the Company , has completed comprehensive product and strategic upgrades. The overhaul includes reconstruction of underlying data architecture, expansion of omnichain data capabilities and optimization of user service frameworks. Concurrently, the platform announced its revised strategic focus: it intends to target the niche market of digital asset information and data services for token-based derivatives, yield instruments and collateralized assets. By pre-emptively building industry data infrastructure, DexTrader hopes to establish a solid foundation for product iteration and market leadership in the future.

As the core data gateway and exclusive on-chain data service arm within DCX’s DeFi ecosystem, DexTrader delivers traffic aggregation, data support and ecosystem coordination. It currently provides one-stop, full-spectrum on-chain data services for retail traders, professional practitioners and institutional clients, supporting users’ independent research and analysis of digital asset markets.

The latest upgrade strengthens DexTrader’s underlying data processing, multi-source data integration and intelligent analytics infrastructure, laying technical groundwork to enter the yield-bearing collateral segment and deploy dual-track data pipelines.

The platform is intended to remedy gaps in general on-chain data services with improved real-time performance, accuracy and data granularity. Backed by DCX’s ecosystem synergies, The Company believes that DexTrader is intended to form an initial closed-loop service system with distinct differentiation to meet diversified on-chain data research and analysis needs.

This iteration advances DCX’s commitment to the DeFi ecosystem, hoping to leverage technological and data innovation to foster sound industrial development. The upgrade is intended to elevate DexTrader’s services from functionally viable to institutionally professional, supporting the DEX sector’s transition from traffic competition to refined, specialized services.

Moving forward, drawing on its upgraded technical framework, DexTrader plans to develop dedicated data services for token ecosystem derivatives and yield-bearing collateral. The platform aims to build a comprehensive data system for yield-bearing collateralized derivatives, and offer global users full-stack, professional, intelligent digital tools for on-chain asset research and analysis.

About Digital Currency X Technology Inc.

Digital Currency X Technology Inc. (Nasdaq: DCX) is a pioneering digital asset treasury management company focused on developing innovative infrastructure for secure cryptocurrency custody and storage solutions. The Company has strategically positioned itself at the forefront of institutional digital asset adoption. The Company is executing a comprehensive digital currency strategy that includes treasury optimization, participation in decentralized finance (DeFi) ecosystems, and development of advanced custody infrastructure.

Investor and Media Contact:

Digital Currency X Technology Inc.

Room 1101, 11/F., Capital Centre, 151 Gloucester Road, Wanchai, Hong Kong

Attention: Ms. Melissa Chen

E-mail: [email protected]

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements include, but are not limited to, statements regarding the Company’s strategy, plans and expectations concerning the continued development, enhancement and operation of DexTrader; the proposed development and rollout of data and analytics services relating to token-based derivatives, yield-bearing instruments and collateralized assets; the anticipated functionality, performance, reliability, data coverage and potential benefits of DexTrader’s technology and services; potential market demand, user adoption, competitive positioning and monetization; the Company’s expansion plans and opportunities in decentralized finance, technology and digital assets; and other statements that are not historical facts and may address activities, events or developments that the Company intends, expects, projects, plans, believes or anticipates will or may occur in the future. These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and assumptions that are difficult to predict, including the risk that planned products, features and services may not be successfully developed, completed, launched or commercialized; that they may not perform as intended or achieve the anticipated accuracy, reliability, user adoption, market acceptance or monetization; that the Company may not have sufficient technical, financial, personnel or other resources to implement its plans; risks relating to the availability, accuracy and continuity of third-party data sources, blockchain networks and other technology dependencies; cybersecurity incidents, software defects, network failures and service interruptions; competition and the rapidly evolving and volatile nature of digital asset markets; and changes in laws, regulations or regulatory interpretations relating to digital assets, derivatives, tokenized assets and related data services. The Company’s actual results, performance or achievements could differ materially from those expressed or implied by the forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those discussed under “Item 3.D. Risk Factors” in the Company’s most recent Annual Report on Form 20-F and in the Company’s other reports filed with or furnished to the Securities and Exchange Commission (“SEC”), including reports on Form 6-K, copies of which are available at www.sec.gov. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.